Teprotumumab (Tepezza) for Thyroid Eye Disease

Keyphrases

• Chemotherapy 25%
• Clinical Aspects 25%
• Diplopia 25%
• Disease-modifying Therapy 25%
• Facial Disfigurement 25%
• Federal Drug Administration 25%
• Immune Response 25%
• Infiltration 25%
• Inflammation 25%
• Inflammatory Diseases 25%
• Inflammatory Phase 25%
• Medical Modalities 25%
• Orbital Radiation 25%
• Orbital Soft Tissue 50%
• Proptosis 25%
• Quality of Life 25%
• Quiescent Infection 25%
• Steroid-sparing 25%
• Surgical Intervention 25%
• Tepezza 100%
• Teprotumumab 100%
• Therapy Interventions 25%
• Thyroid Eye Disease 100%

Medicine and Dentistry

• Clinical Feature 25%
• Deformity 25%
• Diplopia 25%
• Disease Modifying Therapy 25%
• Diseases 25%
• Drug Administration 25%
• Endocrine Ophthalmopathy 100%
• Exophthalmos 25%
• Immunity 25%
• Quality of Life 25%
• Surgery 25%
• Teprotumumab 100%

Immunology and Microbiology

• Graves' Ophthalmopathy 100%
• Immunity 25%
• Soft Tissue 25%
• Teprotumumab 100%